Press Release: The European market for cardiac risk assessment markers.

(From Chemical Business NewsBase: Press Release)

Following a year of unprecedented growth, the European market for cardiac risk assessment markers amassed revenues worth $24 M in 2001. This tremendous pace of market expansion is underpinned by the long-term measures required to tackle the escalating prevalence of congestive heart failure (CHF) caused by the rising proportion of Europe's ageing population. Latest findings by Frost & Sullivan reveal that the widespread adoption of expensive natriuretic peptide (NP)-based assays is largely responsible for expanding interest in cardiac risk assessment markets. Moreover, the ascendancy of troponin as an earlier cardiac …